跳至主要内容
临床试验/NCT02630719
NCT02630719终止不适用

Timolol Eye Drops in the Treatment of Acute Migraine Headache

University of Missouri, Kansas City1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
10
试验地点
1
主要终点
Timolol Eye Drops in the Treatment of Acute Migraine Headache

研究概览

简要总结

The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of migraine headache
  • Exclusion Criteria
  • Non-migraine headache
  • Use of systemic beta-blocker
  • Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease
  • Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease
  • Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications
  • Previous adverse reaction to timolol or other beta-blockers
  • Inability to self-administer eye drop due to physical or cognitive disorders
  • Currently pregnant or breastfeeding
  • Pregnant in the past year
  • Non-english speaker

排除标准

  • 未提供

研究组 & 干预措施

Timolol eye drops

Active Comparator

All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.

干预措施: Timolol eye drops (Drug)

Artificial tears

Placebo Comparator

All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.

干预措施: Artificial tears (Drug)

结局指标

主要结局

Timolol Eye Drops in the Treatment of Acute Migraine Headache

时间窗: 4 months

Percent of migraine attacks at 0 or 1 on the 4-point Rating Scale recommended by the International Headache Society: 0: no headache 1. mild headache 2. moderate headaches 3. severe headache

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sean Gratton

Assistant Professor and Staff Physician

University of Missouri, Kansas City

研究点 (1)

Loading locations...

相似试验